AgeX Therapeutics, Inc. (AGE) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Alameda, CA, United States. वर्तमान CEO हैं Eun-Jae Park CPA.
AGE के पास है IPO तिथि 2018-11-29, 4 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NYSE, बाजार पूंजीकरण $27.76M.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
